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Abstract
Objective—To describe maternal and neonatal morbidity and mortality among women with HIV 
infection and their infants.
Methods—A secondary analysis was undertaken of data obtained in the BAN Study, a trial of 
postnatal antiretrovirals among pregnant women with HIV infection enrolled in 2004–2010. 
Mothers and infants had 13 scheduled visits through 48 weeks of follow-up. Serious maternal 
morbidity and mortality were examined at delivery (n=2791), from delivery to 6 weeks later 
(n=2369) and from 7 to 48 weeks (n=1980). Neonatal morbidity and mortality were examined 
(n=2685).
Results—Of 2791 deliveries, 169 (6.1%) were by cesarean (153 emergency). Compared with 
women with vaginal delivery, those with cesarean delivery had lower prenatal HIV viral loads 
(P=0.016) and increased odds of pre-eclampsia/eclampsia (odds ratio [OR] 10.8, 95% CI 4.4–
26.8). Women with cesarean delivery also had increased odds of serious infection with 14 days of 
delivery (OR 3.0, 95% CI 1.3–7.4) and severe anemia (grade 3 or 4) by 6 weeks (OR 6.7, 95% CI 
2.3–19.1). Infants born by cesarean had increased odds of a low 5-minute Apgar score (OR 8.1, 
95% CI 3.5–18.6) and admission to an intensive care unit (OR 5.4, 95% CI 3.7–7.8).
Conclusion—Odds of serious maternal and neonatal morbidity were higher after cesarean than 
vaginal delivery, despite lower maternal viral loads.
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1 INTRODUCTION
Approximately 18 million women are living with HIV type 1 infection worldwide.1 
Globally, HIV infection and maternal mortality remain the two leading causes of death for 
women aged 15–49 years.2 Pregnant women with HIV infection have an estimated maternal 
mortality almost eight times higher than that of uninfected women,3 and in areas with high 
prevalence, HIV infection is estimated to account for 12%–50% of maternal deaths.4
Pregnancy-related morbidity is also increased in women with HIV infection: their risk of 
major puerperal sepsis is two times higher than that of uninfected women, and their risk of 
preterm labor and delivery is increased by 30%, even after adjusting for comorbidities, 
socioeconomic factors, and treatment with antiretroviral (ARV) therapy.5 Increased risks of 
postpartum and neonatal morbidity have also been suggested with both elective and 
emergency cesarean delivery compared with vaginal delivery.6,7 Most of this evidence 
derives from resource-rich settings, and maternal morbidity and mortality among women 
with HIV infection in resource-limited settings was recently identified as a priority for 
researchers and stakeholders to assess and develop appropriate public health interventions.8
To better describe maternal and neonatal outcomes among women with HIV infection and 
their infants in a resource-limited setting, a secondary analysis was undertaken of the 
Breastfeeding, Antiretrovirals, and Nutrition (BAN) Study, a clinical trial among 2369 
mother–infant pairs.9 The aims of the present secondary analysis were to describe serious 
maternal and neonatal morbidity and mortality among women with HIV infection and their 
infants, overall and by delivery type, and to determine risk factors for postpartum maternal 
complications or mortality.
2 MATERIALS AND METHODS
Full details of the BAN Study—a randomized clinical trial of postnatal ARVs for prevention 
of HIV transmission during breastfeeding—have been reported previously.9 Briefly, between 
April 2004 and January 2010, 3572 pregnant women with HIV infection referred to the BAN 
study clinic at Bwaila Hospital in Lilongwe, Malawi, were screened for enrollment in the 
BAN Study (Figure 1). Overall, 3109 met the prenatal eligibility criteria: aged 14 years or 
older, pregnancy of 30 weeks or less, CD4+ T-cell count of at least 250 cells per μL (≥200 
cells per μL before July 24, 2006; change in accordance with Malawi Ministry of Health 
guidelines for HIV treatment), hemoglobin of 70 g/L or higher, an alanine aminotransferase 
concentration of no more than 2.5 times the upper limit of the normal range, no presence of 
other active serious infection, and no previous use of any ARV agents. Women who met 
these criteria were enrolled and followed up prospectively for up to four prenatal study 
visits, at which they received iron and folate supplements, screening for anemia and syphilis, 
malaria prophylaxis, mosquito nets, and tetanus toxoid vaccination. Co-trimoxazole 
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prophylaxis was initiated for eligible women (CD4+ <500 cells per μL) and all infants in 
June 2006, in accordance with WHO guidelines.10
The women were asked to deliver at Bwaila Hospital. However, women who delivered 
elsewhere (21.7%) were eligible for randomization to the BAN interventions if the mother 
and neonate arrived at the hospital within 36 hours of delivery. The BAN Study captured 
2791 (89.8%) of the 3109 women’s deliveries, and the current secondary analysis presents 
the labor and delivery characteristics of these women and their neonates. On delivery, 2382 
women met the postnatal eligibility criteria for randomization to the BAN Study 
interventions. These criteria included neonatal birth weight of 2000 g or more, the mother’s 
acceptance of a 7-day maternal and neonatal perinatal ARV regimen, enrollment within 36 
hours of delivery, and the exclusion of any serious maternal or infant medical conditions that 
would preclude participation in the study. Postpartum complications beyond the delivery 
visit are presented among this group of mothers and their infants.
At delivery, all 2791 mothers and neonates received single-dose nevirapine (Viramune, 
Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT, USA), followed by 1 week of twice 
daily zidovudine and lamivudine (Combivir [GlaxoSmithKline and Shire Pharmaceuticals 
Group, Basingstoke, UK] for mothers, and Retrovir [GlaxoSmithKline, Zebulon, NC, USA] 
and Epivir (GlaxoSmithKline and Shire Pharmaceuticals Group, Basingstoke, UK) for 
infants). Within a week of delivery, 2369 mother–infant pairs underwent randomization 
using a factorial design to a two-group maternal nutritional intervention and a three-group 
ARV intervention consisting of a maternal triple-drug ARV regimen (n=879), infant 
nevirapine (n=852), or neither (n=668) during breastfeeding. Mothers were counseled to 
exclusively breastfeed for 24 weeks, then wean over 4 weeks to complete breastfeeding by 
28 weeks after delivery.
The 2369 mother–infant pairs were followed up at 1, 2, 4, 6, 8, 12, 18, 21, 24, 32, 36, 42, 
and 48 weeks after delivery. At each visit, anthropometrics, vital signs, and medical history 
were collected and a complete physical examination was performed on the mother and 
infant. All infants received routine vaccinations which included Bacillus Calmette–Guérin, 
polio, diphtheria, pertussis, tetanus, Haemophilus influenza, hepatitis B, and measles. Infants 
who tested positive for HIV infection were referred to care, and these mother–infant pairs 
were no longer followed up. Participants were counseled to return to the study site for care 
between visits if either the mother or child became ill. If a condition identified at a follow-up 
or interim visit met the criteria for an adverse event or a serious adverse event, it was 
documented on the appropriate study form.
The BAN Study protocol was approved by the Malawi National Health Science Research 
Committee and institutional review boards at the University of North Carolina at Chapel Hill 
and the US Centers for Disease Control and Prevention. All women provided written 
informed consent.
For the present analysis, serious maternal morbidity and mortality were examined at delivery 
(n=2791), from delivery to 6 weeks later (n=2369), and from 7 to 48 weeks (n=1980). 
Neonatal morbidity was examined for all singletons and first-born infants in multiple 
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deliveries who had an initial infant evaluation form completed (n=2685). In addition to that 
infant form, maternal and neonatal morbidity outcomes were derived from delivery history 
questionnaires and records of laboratory adverse events and serious adverse events. Adverse 
events were graded using normative value cutoffs from toxicity tables for adults or infants 
from the National Institute of Health, Division of AIDS.11 Serious adverse events were 
defined as any fatal or life-threatening event requiring hospitalization or prolongation of 
hospital stay, or which resulted in persistent or significant disability. Maternal mortality was 
defined as any death that occurred from delivery to 48 weeks. Neonatal death was defined as 
death by 28 days of life, and was assessed among singletons and first-born infants.
Maternal morbidity is defined as any health condition attributed to and/or aggravated by 
pregnancy and childbirth that has a negative impact on the woman’s well-being.12 For the 
present analysis, maternal morbidities were presented separately for delivery (pre-eclampsia/
eclampsia, hemorrhage, blood transfusion, intrapartum fever, puerperal sepsis/endometritis, 
stillbirth, and prolonged hospital stay) and postpartum (infection, grade 1–4 anemia) 
complications. Delivery complications were analyzed for all mothers who delivered during 
the study (n=2791). A “prolonged hospital stay” was defined as admission to the postpartum 
ward for more than 48 hours after vaginal delivery and more than 7 days after cesarean 
delivery. Stillbirth was defined as fetal loss at 20 weeks’ gestation or more. The category 
“obstetric complications” included pre-eclampsia/eclampsia documented at delivery, 
maternal hemorrhage, blood transfusion, stillbirth, prolonged hospitalization stay, and 
infection up to 14 days after delivery. Postpartum complications were only assessed for 
women who underwent randomization (n=2369). “Infection” includes all instances of 
puerperal sepsis/endometritis, serious febrile illness/sepsis, malaria, intrapartum fever, 
pneumonia, meningitis, tuberculosis, pelvic inflammatory disease, and syphilis at delivery or 
from delivery to 2 weeks if a serious adverse event. Neonatal morbidity was defined as a low 
Apgar score, admission to the intensive care unit, low birth weight, macrosomia, or neonatal 
sepsis.
The data were stratified by mode of delivery: vaginal delivery, which includes natural 
spontaneous vaginal deliveries and vacuum deliveries; and cesarean delivery, which includes 
elective and emergency cesareans. Maternal and infant baseline characteristics were 
compared by mode of delivery using the Wilcoxon rank-sum test for continuous variables 
and X2 test for categorical variables. Potential predictors for maternal outcomes were 
evaluated with a manual backwards logistic regression (P<0.1 to stay); associations with 
neonatal outcomes have been reported previously.13 The outcomes assessed were prolonged 
hospital stay, infection up to 14 days after delivery, anemia up to 6 weeks after delivery, and 
mortality up to 48 weeks after delivery. Potential predictors included mode of delivery, 
maternal age (>29 years), body mass index (<20, calculated as weight in kilograms divided 
by the square of height in meters), CD4+ T-cell count (<500 cells per μL), log HIV viral 
load, prenatal anemia (hemoglobin <110 g/L), and hemorrhage. All analyses were adjusted 
for the maternal ARV and nutritional study group. Data were analyzed using SAS 9.3 (SAS 
Institute, Cary, NC, USA). P<0.05 was considered significant.
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Of the 2791 deliveries, 2622 (93.9%) were vaginal (2582 natural spontaneous, 40 vacuum) 
and 169 (6.1%) by cesarean (16 elective, 153 emergency). The location of delivery was a 
health facility for 2387 (85.5%) women, home for 237 (8.5%), and “other” for 159 (5.7%). 
Table 1 shows maternal characteristics. The median age at delivery was 25 years; 1841 
(66.0%) had only primary education, and 2426 (86.9%) had one or more previous 
pregnancies. Women who delivered by cesarean had a significantly lower median prenatal 
HIV viral load than did women who delivered vaginally (P=0.016). Women who delivered 
by cesarean were also more likely to have higher than primary education and be 
primigravidas compared with those who delivered vaginally (Table 1).
Obstetric complications within 2 weeks of delivery were reported for 243 (8.7%) mothers. A 
prolonged hospital stay and infection were the most frequent within the first 2 weeks (Table 
2). Compared with vaginal delivery, cesarean delivery was associated with 8-times higher 
overall odds of complications; odds of individual complications such as pre-eclampsia/
eclampsia at delivery, stillbirth, prolonged hospitalization, and infection by 2 weeks were 
also increased with cesarean (Table 2).
Within 6 weeks of delivery, 834 (35.3%) of 2365 mothers had documented anemia of grade 
1–2 and 18 (0.8%) had anemia of grade 3–4. Women with cesarean delivery had 
significantly higher odds of anemia of both grade 1–2 and grade 3–4 than did women who 
had a vaginal delivery (Table 2).
After adjustment for the maternal ARV and nutritional intervention group and other factors, 
cesarean delivery remained significantly associated with prolonged hospital stay (adjusted 
odds ratio [aOR] 16.2, 95% confidence interval [CI] 10.0–26.5), infection within 2 weeks of 
delivery (aOR 3.3, 95% CI 1.4–8.1), and anemia within 6 weeks (aOR 5.6, 95% CI 3.8–8.5). 
In addition to cesarean delivery, other significant predictors of prolonged hospital stay in 
multivariable analysis were hemorrhage (aOR 57.1, 95% CI 23.7–137.9) and maternal age 
older than 29 years (aOR 1.7, 95% CI 1.1–2.7). Additional predictors of infection within 2 
weeks of delivery included prenatal anemia (aOR 2.5, 95% CI 1.3–5.0) and postpartum 
hemorrhage (aOR 9.0, 95% CI 2.5–32.2). Predictors of anemia in addition to cesarean 
delivery were prenatal anemia (aOR 5.2, 95% CI 4.2–6.3) and hemorrhage (aOR 13.1, 95% 
CI 4.3–40.0).
There were no maternal deaths in the first 42 days after delivery, but 9 (0.5%) of the 1980 
women followed up through 48 weeks died: three due to complications of tuberculosis, two 
due to renal failure, and one each due to hepatic necrosis, pneumonia, perforated viscus, and 
unknown cause. Cesarean delivery was not associated with maternal mortality (Table 2), but 
women with postpartum anemia (≤48 weeks; hemoglobin <110 g/L) had four-times higher 
odds of mortality than did mothers without anemia (aOR 4.8, 95% CI 1.2–19.4).
Stillbirth was recorded for 45 (1.7%) of 2649 infants. Low birth weight (>2000 g and ≤2500 
g) was recorded for 283 (10.6%) of 2670 neonates, and 239 (8.9%) of 2679 were admitted to 
an intensive care unit. Cesarean delivery was associated with increased odds of low Apgar 
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scores at 5 minutes and admission to an intensive care unit compared with vaginal delivery 
(Table 3).
There were 12 (0.4%) neonatal deaths, which occurred in the first 22 days of life: six from 
neonatal sepsis, three from pneumonia, one from sudden infant death of unknown etiology, 
one from complications of diabetes insipidus, and one from an acute illness of unknown 
etiology. There was no significant association between mode of delivery and neonatal death 
(Table 3). The neonatal mortality rate was 4.5 neonatal deaths per 1000 live births. Including 
stillbirths with neonatal deaths, the combined mortality rate was 20.6 per 1000 births.
4 DISCUSSION
In the present study, 9% of mothers had one or more complication within 2 weeks of 
delivery, with the odds of any complication significantly increased with cesarean delivery. 
Cesarean delivery was also associated with blood loss and increased odds of pre-eclampsia/
eclampsia at delivery, stillbirth, prolonged hospital stay, infection within the first 14 days, 
and anemia within 6 weeks of delivery. Neonates born by cesarean also had higher odds of 
complications than did those delivered vaginally, including a low 5-minute Apgar score and 
admission to an intensive care unit. These results highlight potential areas for improved 
outcomes and CD practices.
Cesareans have previously been associated with increased postpartum morbidity among 
women with and without HIV infection in resource-rich and resource-limited settings.6,7,14 
The risk of complications is highest for emergency cesarean delivery, and intermediate for 
elective cesarean.6 In Malawi, cesarean delivery is rare (4.6%) and mostly performed as an 
emergency without preoperative preparation,15 so it is not surprising that 91% of cesareans 
in the BAN Study were emergency procedures and had a higher complication rate than 
vaginal deliveries.
More than one-third of BAN mothers were anemic within 6 weeks of delivery, and the 
strongest predictors for postpartum anemia were prenatal anemia, cesarean delivery, and 
obstetric hemorrhage. Prenatal and postpartum anemia were associated with maternal 
infection within 2 weeks of delivery and maternal mortality by 48 weeks, respectively. In a 
matched-pairs analysis of Swiss women with and without HIV infection undergoing elective 
cesarean delivery,16 postoperative anemia occurred in 49% of women with HIV infection 
and 9% of uninfected women. In the European Collaborative Study,17 mild anemia was the 
most prevalent complication among women with and without HIV infection after cesarean 
delivery, but it was more frequent among women with HIV infection. In Malawi, the 
prevalences of anemia and severe anemia (grade 3–4) during pregnancy range from 39% to 
72% and 3.6% to 4.0%, respectively.18 The estimated relative risks of mortality associated 
with moderate and severe anemia for women in low-income countries have been reported as 
1.35 and 3.51, respectively.18 The women in the BAN Study received iron and folate 
supplements and underwent screening for anemia, which could explain the lower anemia 
prevalence in this HIV cohort compared with the other estimates from Malawi. These data 
suggest that prenatal surveillance and improved nutritional supplementation with iron-rich 
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foods and/or vitamin supplements might reduce anemia-related morbidity and mortality in 
resource-limited settings.
Low maternal CD4+ count and high HIV-1 viral load have been associated with maternal 
and infant mortality in previous studies.19,20 However, we did not find such significant 
associations when evaluating severe (CD4 <200 cells per μL) or moderate (CD4+ 200–500 
cells per μL) levels of immunosuppression. The women who enrolled in the BAN Study had 
CD4 counts of more than 200 cells per μL, and most had viral loads of less than 50 000 
copies per mL; thus, analyses of the effect of advanced HIV disease were limited.
Maternal and neonatal deaths were rare. Worldwide, 75% of maternal deaths are due to 
hemorrhage, infection, severe pre-eclampsia/eclampsia, complications of delivery, and 
unsafe abortion; the remaining deaths are due to indirect causes such as malaria, HIV/AIDS, 
anemia, and tuberculosis.21 In Malawi, hemorrhage, infection, and hypertensive disorders of 
pregnancy are the three leading causes of maternal death;22 the maternal mortality ratio is 
estimated as 680 deaths per 100 000 live births.23 In the present study, maternal mortality 
was zero during the immediate postpartum period (up to 6 weeks after delivery), and 0.5% 
by 48 weeks. All maternal deaths were due to indirect causes, mainly complications of HIV. 
The Malawi Demographic and Health Survey24 reported a neonatal mortality rate of 27 
deaths per 1000 live births; in the present study, the rate was estimated as 4.5 per 1000 live 
births. The reduced maternal and neonatal mortality in BAN—despite including a population 
of women with HIV infection and their infants—could be attributed to enhanced prenatal 
and postpartum medical monitoring and clinical care. The frequent medical follow-up and 
provision of vaccines, prophylactic drugs, and nutritional supplements for all participants 
exceeds the standard of care for Malawi, highlighting achievable goals for this resource-
limited setting.
Strengths of the present secondary analysis are the large sample size and well-documented 
medical follow-up of BAN participants. Health facility deliveries were more frequent in the 
BAN Study (86%) compared with the country overall (73%),25 which could affect 
comparisons.14 Limitations include the rarity of elective cesarean delivery, which prohibited 
statistical comparisons by type of cesarean, and the lack of a comparison group of women 
without HIV infection. Other limitations were that only serious clinical events (those 
necessitating or prolonging hospitalization) were included. Additionally, as with all large, 
longitudinal studies, there were missing data. For four factors assessed (baseline viral load, 
body mass index, estimated blood loss, and Apgar score at 5 minutes), the proportion of 
missing data differed significantly between vaginal and cesarean deliveries; missing data 
could have affected the results.
The present study provides frequencies and predictors of maternal and neonatal morbidities 
by delivery type among women with HIV infection before the introduction of prenatal ARV 
therapy in Malawi. As option B+ rolls out in the country and women with HIV infection are 
given ARV therapy before delivery,26 these data can provide a comparison for tracking the 
effectiveness of prenatal ARV therapy on maternal and neonatal outcomes among women 
with HIV infection in similar settings.
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Odds of serious maternal and neonatal morbidity were higher after cesarean than vaginal 
delivery, despite lower maternal viral loads.
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Enrollment of mother–infant pairs.
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Table 2
Labor characteristics and maternal morbidity and mortality, by delivery type.a
Characteristic/complication All mothers Delivery method
Vaginal delivery Cesarean delivery Odds ratio (95% confidence interval)b
Labor and delivery characteristics
 Pre-eclampsia/eclampsia 20/2791 (0.7) 12/2622 (0.5) 8/169 (4.7) 10.8 (4.4–26.8)
 Estimated blood loss, mLc 100 (100–200) 100 (100–150) 500 (300–800) –d
 Hemorrhage 32/2791 (1.1) 32/2622 (1.2) 0/169 0.2 (0.0–3.9)
 Blood transfusion 11/2791 (0.4) 9/2622 (0.3) 2/169 (1.2) 3.5 (0.8–16.2)
 Intrapartum fever 5/2791 (0.2) 4/2622 (0.2) 1/169 (0.6) 3.9 (0.4–35.1)
 Puerperal sepsis/endometritis 22/2791 (0.8) 21/2622 (0.8) 1/169 (0.6) 0.7 (0.1–5.5)
 Stillbirths 45/2649 (1.7) 39/2488 (1.6) 6/161 (3.7) 2.4 (1.0–5.8)
 Prolonged hospital staye 151/2778 (5.4) 105/2609 (4.0) 46/169 (27.2) 8.9 (6.0–13.2)
Postpartum complications
 Infection ≤14 d after deliveryf 42/2369 (1.8) 36/2238 (1.6) 6/131 (4.6) 3.0 (1.3–7.4)
 Anemia ≤6 wk after delivery
  Grade 1 and 2g 834/2365 (35.3) 745/2234 (33.3) 89/131 (67.9) 4.3 (2.9–6.2)
  Grade 3 and 4h 18/2365 (0.8) 13/2234 (0.6) 5/131 (3.8) 6.7 (2.3–19.1)
All obstetric complicationsi 243/2791 (8.7) 182/2622 (6.9) 61/169 (36.1) 8.0 (5.3–12.0)
Mortality
 0–6 wk after delivery 0/2369 – – –
 7–48 wk after delivery 9/1980 (0.5) 8/1871 (0.4) 1/109 (0.9) 2.1 (0.3–17.3)
a
Values are given as number/total number (percentage) unless indicated otherwise.
b
Compare outcomes for cesarean and vaginal deliveries (referent group). For postpartum complications beyond delivery, they were adjusted for the 
antiretroviral and nutritional intervention group.
c
Values are given as median (interquartile range). Data missing for 757 (731 vaginal delivery, 26 cesarean delivery). The proportion of missing data 
differed significantly by delivery method, with a lower proportion of cesarean deliveries missing this information (P<0.001).
d
P<0.001 (Wilcoxon rank-sum test).
e
>48 h after natural spontaneous vaginal delivery; >7 d after cesarean delivery.
f







Hemorrhage, pre-eclampsia/eclampsia, prolonged hospital stay, blood transfusion, stillbirth, and infection from delivery until 2 weeks after 
delivery. Women with multiple complications were only counted once.
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Table 3
Neonatal complications by delivery type.a
Complication All mothers (n=2685) Delivery method
Vaginal delivery (n=2531) Cesarean delivery (n=154) Odds ratio (95% 
confidence 
interval)b
5-min Apgar score <7c 25 (1.1) 16 (0.8) 9 (5.9) 8.1 (3.5–18.6)
Admission to an intensive 
care unitd
239 (8.9) 192 (7.6) 47 (30.7) 5.4 (3.7–7.8)
Low birth weighte,f 283 (10.6) 261 (10.4) 22 (14.5) 1.5 (0.9–2.3)
Macrosomiae,g 35 (1.3) 32 (1.3) 3 (2.0) 1.6 (0.5–5.2)
Neonatal sepsis 106 (3.9) 100 (4.0) 6 (3.9) 1.0 (0.4–2.3)
Neonatal mortality 12 (0.4) 10 (0.4) 2 (1.3) 3.3 (0.7–15.3)
a
Values are given as number (percentage) unless indicated otherwise.
b
Odds ratios from logistic regression compare cesarean with vaginal deliveries (referent group).
c
Data missing for 464 (462 vaginal delivery, 2 cesarean delivery). The proportion of missing data differed significantly by delivery method, with a 
lower proportion of cesarean deliveries missing this information.
d
Data missing for 6 (5 vaginal delivery, 1 cesarean delivery).
e
Data missing for 15 (13 vaginal delivery, 2 cesarean delivery).
f
>2000g and ≤2500 g.
g
>4000 g.
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